bluebird bio, Inc. (NASDAQ:BLUE) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET
Company Participants
Courtney O'Leary - Director of Investor Relations
Andrew Obenshain - Chief Executive Officer
Tom Klima - Chief Commercial and Operating Officer
Chris Krawtschuk - Chief Financial Officer
Conference Call Participants
Dane Leone - RJF
Jason Gerberry - Bank of America Securities
Eric Joseph - JPMorgan
Jack Allen - Baird
Gena Wang - Barclays
Mani Foroohar - Leerink
Eric Schmidt - Cantor Fitzgerald
Yanan Zhu - Wells Fargo
Luca Issi - RBC Capital
Sami Corwin - William Blair
Michael Riad - Morgan Stanley
Operator
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the bluebird bio Third Quarter 2023 Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]
At this time, I would like to turn the conference over to your host, Ms. Courtney O'Leary. Ma'am, please begin.
Courtney O'Leary
Good morning, everyone, and thank you for joining our third quarter results call today. My name is Courtney O'Leary, Director of Investor Relations at bluebird bio.
Before we begin, let me review our Safe Harbor statement. Today's discussion contains statements that are forward-looking under the Private Securities Litigation Reform Act of 1995, including expectations regarding our future financial results and financial position in addition to statements of the company's plans, expectations or intentions regarding regulatory progress, commercialization plans, and business operations.
Such statements are based on current expectations and assumptions that are subject to risks and uncertainties and involve a number of risk factors that could cause actual results to differ materially from projected results. A description of these risks is contained in our filings with the SEC, which are available on the Investor Relations section of our website, www.bluebirdbio.com.
On today's call, Andrew Obenshain, our CEO, is going to provide some opening remarks on our overall business and potential lovo-cel approval. Then, Tom Klima, Chief Commercial and Operating Officer, will discuss the positive momentum in our ZYNTEGLO and SKYSONA commercial launches as well as launch preparations for lovo-cel. And finally, Chris Krawtschuk, Chief Financial Officer, will provide some color on our financial results, before opening the call up for Q&A.
With that, I will turn it over to Andrew.
Andrew Obenshain
Thanks, Courtney, and thank you, everyone, for joining our call this morning.